1 option
CADTH Canadian Drug Expert Committee final recommendation : Indication: pulmonary arterial hypertension. Selexipag (Uptravi -- Actelion Pharmaceuticals Canada Inc.) / Canadian Agency for Drugs and Technologies in Health.
- Format:
- Book
- Author/Creator:
- Canadian Agency for Drugs and Technologies in Health, author, issuing body.
- Language:
- English
- Subjects (All):
- Outcome assessment (Medical care).
- Cost effectiveness.
- Physical Description:
- 1 online resource (6 pages)
- Place of Publication:
- Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2016.
- Summary:
- The CADTH Canadian Drug Expert Committee (CDEC) recommends that selexipag be reimbursed for long-term treatment of idiopathic pulmonary arterial hypertension (PAH), heritable HPAH, PAH associated with connective tissue disorders, and PAH associated with congenital heart disease, in adult patients with World Health Organization (WHO) functional class (FC) II to III to delay disease progression.
- Notes:
- Description based on publisher supplied metadata and other sources.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.